De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Chemed Beheer

Beheer criteriumcontroles 3/4

De CEO Chemed's is Kevin McNamara, benoemd in Aug1994, heeft een ambtstermijn van 30.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 12.63M, bestaande uit 12.7% salaris en 87.3% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.69% van de aandelen van het bedrijf, ter waarde $ 62.34M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 24.4 jaar en 15.4 jaar.

Belangrijke informatie

Kevin McNamara

Algemeen directeur

US$12.6m

Totale compensatie

Percentage CEO-salaris	12.7%
Dienstverband CEO	30.2yrs
Eigendom CEO	0.7%
Management gemiddelde ambtstermijn	24.4yrs
Gemiddelde ambtstermijn bestuur	15.4yrs

Recente managementupdates

Recent updates

Here's Why Chemed Corporation's (NYSE:CHE) CEO Compensation Is The Least Of Shareholders' Concerns

May 14

Is Chemed Corporation (NYSE:CHE) Trading At A 50% Discount?

Apr 26

Chemed Corporation (NYSE:CHE) Full-Year Results: Here's What Analysts Are Forecasting For This Year

Mar 01

The Price Is Right For Chemed Corporation (NYSE:CHE)

Dec 30

Chemed: Continues To Compound Shareholder Value At Double-Digit Returns

Nov 30

Chemed (NYSE:CHE) Is Aiming To Keep Up Its Impressive Returns

Oct 26

Chemed - Showcasing Why It's So Reliable

Aug 26

Chemed: Still Bullish On Economic Characteristics, But Risks Shouldn't Be Overlooked

Aug 13

Is Chemed Corporation (NYSE:CHE) Worth US$521 Based On Its Intrinsic Value?

Aug 01

Capital Investments At Chemed (NYSE:CHE) Point To A Promising Future

Jul 14

Chemed (NYSE:CHE) Has A Rock Solid Balance Sheet

Jun 07

Chemed (NYSE:CHE) Is Aiming To Keep Up Its Impressive Returns

Apr 09

Chemed Q4 2022 Earnings Preview

Feb 22

Chemed Corporation: Long-Term Tailwinds, But Remains A Hold

Feb 14

Is Chemed (NYSE:CHE) Using Too Much Debt?

Jan 05

Here's What Chemed's (NYSE:CHE) Strong Returns On Capital Mean

Dec 17

Chemed declares $0.38 dividend

Nov 04

Chemed Q3 2022 Earnings Preview

Oct 28

Does Chemed (NYSE:CHE) Have A Healthy Balance Sheet?

Oct 01

Capital Investment Trends At Chemed (NYSE:CHE) Look Strong

Sep 16

Buy Chemed To Reduce Equity Beta And Stabilize Portfolio Returns

Aug 26

A Look At The Intrinsic Value Of Chemed Corporation (NYSE:CHE)

Aug 16

Analyse CEO-vergoeding

Hoe is Kevin McNamara's beloning veranderd ten opzichte van Chemed's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$301m
Mar 31 2024	n/a	n/a	US$283m
Dec 31 2023	US$13m	US$2m	US$273m
Sep 30 2023	n/a	n/a	US$245m
Jun 30 2023	n/a	n/a	US$226m
Mar 31 2023	n/a	n/a	US$240m
Dec 31 2022	US$12m	US$1m	US$250m
Sep 30 2022	n/a	n/a	US$262m
Jun 30 2022	n/a	n/a	US$277m
Mar 31 2022	n/a	n/a	US$267m
Dec 31 2021	US$12m	US$1m	US$269m
Sep 30 2021	n/a	n/a	US$308m
Jun 30 2021	n/a	n/a	US$303m
Mar 31 2021	n/a	n/a	US$329m
Dec 31 2020	US$12m	US$1m	US$319m
Sep 30 2020	n/a	n/a	US$271m
Jun 30 2020	n/a	n/a	US$263m
Mar 31 2020	n/a	n/a	US$231m
Dec 31 2019	US$10m	US$1m	US$220m
Sep 30 2019	n/a	n/a	US$209m
Jun 30 2019	n/a	n/a	US$201m
Mar 31 2019	n/a	n/a	US$205m
Dec 31 2018	US$9m	US$1m	US$206m
Sep 30 2018	n/a	n/a	US$206m
Jun 30 2018	n/a	n/a	US$190m
Mar 31 2018	n/a	n/a	US$113m
Dec 31 2017	US$8m	US$1m	US$98m

Compensatie versus markt: De totale vergoeding ($USD 12.63M ) Kevin } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 8.11M ).

Compensatie versus inkomsten: De vergoeding van Kevin is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Kevin McNamara (70 yo)

30.2yrs

Tenure

US$12,625,106

Compensatie

Mr. Kevin J. McNamara has been the Chief Executive Officer of Chemed Corporation since May 2001 and has been its President since August 2, 1994. Previously, Mr. McNamara served as an Executive Vice Preside...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kevin McNamara	CEO, President & Director	30.2yrs	US$12.63m	0.69% $ 61.5m
Michael Witzeman	VP, Controller	12.4yrs	US$2.93m	0.025% $ 2.2m
Spencer Lee	Executive Vice President	24.4yrs	US$3.37m	0.13% $ 11.9m
Thomas Hutton	VP & Director	36.7yrs	geen gegevens	0.56% $ 49.7m
Nicholas Westfall	Executive Vice President	8.3yrs	US$4.71m	0.041% $ 3.6m
Lisa Reinhard	VP, Chief Administrative Officer & Secretary	29.9yrs	geen gegevens	geen gegevens
Sherri Warner	Director of Investor Relations	no data	geen gegevens	geen gegevens
Brian Judkins	VP, Secretary & Chief Legal Officer	4.2yrs	geen gegevens	0.0095% $ 843.0k
Nathan McNamara	VP & Chief Strategy Officer	no data	geen gegevens	geen gegevens

24.4yrs

Gemiddelde duur

52.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CHE is doorgewinterd en ervaren (gemiddelde ambtstermijn van 24.4 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Kevin McNamara	CEO, President & Director	37.8yrs	US$12.63m	0.69% $ 61.5m
Thomas Hutton	VP & Director	39.8yrs	geen gegevens	0.56% $ 49.7m
Thomas Rice	Independent Director	15.4yrs	US$278.27k	0.040% $ 3.6m
Sandra Laney	Director Emeritus	15.4yrs	US$157.02k	geen gegevens
Patrick Grace	Independent Director	28.8yrs	US$308.60k	0.022% $ 1.9m
George Walsh	Independent Chairman	29.8yrs	US$453.15k	0.023% $ 2.1m
Andrea Lindell	Independent Director	16.4yrs	US$272.77k	0.038% $ 3.4m
Christopher Heaney	Independent Director	4.4yrs	US$279.43k	0.014% $ 1.3m
Ron DeLyons	Independent Director	4.4yrs	US$278.27k	0.0093% $ 823.4k
John Mount	Independent Director	2.2yrs	US$278.27k	0.0043% $ 386.8k
Eileen McCarthy	Independent Director	1.4yrs	US$238.52k	0.0039% $ 342.3k

15.4yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CHE zijn ervaren en ervaren (gemiddelde ambtstermijn van 15.4 jaar).

Chemed Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

CEO, President & Director recently sold US$1.2m worth of stock

Executive Vice President recently sold US$975k worth of stock

Executive Vice President exercised options and sold US$1.6m worth of stock

VP & Director notifies of intention to sell stock

Executive Vice President recently sold US$1.1m worth of stock

Executive Vice President notifies of intention to sell stock

Recent updates

CEO, President & Director recently sold US$1.2m worth of stock

Chemed Corporation to Report Q3, 2024 Results on Oct 29, 2024

Executive Vice President recently sold US$975k worth of stock

Executive Vice President exercised options and sold US$1.6m worth of stock

Capital Investments At Chemed (NYSE:CHE) Point To A Promising Future

Chemed Remains A Buy On Long-Term Economics

VP & Director notifies of intention to sell stock

Second quarter dividend increased to US$0.50

Chemed Corporation Declares Quarterly Dividend, Payable on August 30, 2024

Executive Vice President recently sold US$1.1m worth of stock

Executive Vice President notifies of intention to sell stock

Second quarter 2024 earnings: EPS misses analyst expectations

Chemed Corporation's (NYSE:CHE) Shares May Have Run Too Fast Too Soon

Chemed Corporation to Report Q2, 2024 Results on Jul 24, 2024

CEO, President & Director recently sold US$816k worth of stock

CEO, President & Director notifies of intention to sell stock

First quarter dividend of US$0.40 announced

Chemed Corporation Declares Quarterly Dividend, Payable on June 18, 2024

Chemed: Growth Does Not Justify The Current Stock Price

CEO, President & Director recently sold US$2.3m worth of stock

Here's Why Chemed Corporation's (NYSE:CHE) CEO Compensation Is The Least Of Shareholders' Concerns

Is Chemed Corporation (NYSE:CHE) Trading At A 50% Discount?

Chemed Corporation Reiterates Earnings Guidance for Full Year 2024

First quarter 2024 earnings: EPS misses analyst expectations

Chemed Corporation, Annual General Meeting, May 20, 2024

New major risk - Revenue and earnings growth

Executive Vice President exercised options and sold US$3.8m worth of stock

Executive Vice President recently sold US$1.3m worth of stock

Chemed Corporation to Report Q1, 2024 Results on Apr 24, 2024

Price target increased by 10% to US$690

Chemed Corporation (NYSE:CHE) Full-Year Results: Here's What Analysts Are Forecasting For This Year

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Now 22% overvalued after recent price rise

Third quarter dividend of US$0.40 announced

Chemed Corporation Declares Quarterly Dividend, Payable on March 15, 2024

Chemed Corporation to Report Q4, 2023 Results on Feb 27, 2024

The Price Is Right For Chemed Corporation (NYSE:CHE)

Chemed Corporation Appoints Michael D. Witzeman as Chief Financial Officer, Effective January 1, 2024

CEO, President & Director recently sold US$859k worth of stock

Chemed: Continues To Compound Shareholder Value At Double-Digit Returns

Executive Vice President recently sold US$580k worth of stock

Executive VP & CFO notifies of intention to sell stock

Chemed Corporation Announces the Retirement of David P. Williams as Chief Financial Officer Effective December 31, 2023

Chemed Corporation Announces the Retirement of David P. Williams as Chief Financial Officer Effective December 31, 2023

Executive VP & CFO exercised options to buy US$5.9m worth of stock.

CEO, President & Director recently sold US$1.7m worth of stock

Chemed Corporation Provides Earnings Guidance for the Full-Year 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Chemed (NYSE:CHE) Is Aiming To Keep Up Its Impressive Returns

Chemed Corporation to Report Q3, 2023 Results on Oct 25, 2023

Chemed - Showcasing Why It's So Reliable

Chemed: Still Bullish On Economic Characteristics, But Risks Shouldn't Be Overlooked

CEO, President & Director recently sold US$2.1m worth of stock

Is Chemed Corporation (NYSE:CHE) Worth US$521 Based On Its Intrinsic Value?

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Capital Investments At Chemed (NYSE:CHE) Point To A Promising Future

Chemed Corporation to Report Q2, 2023 Results on Jul 26, 2023

Chemed (NYSE:CHE) Has A Rock Solid Balance Sheet

Executive Vice President notifies of intention to sell stock

Independent Director recently sold US$160k worth of stock

Independent Director notifies of intention to sell stock

CEO, President & Director recently sold US$2.2m worth of stock

CEO, President & Director exercised options and sold US$412k worth of stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Chemed (NYSE:CHE) Is Aiming To Keep Up Its Impressive Returns

CEO, President & Director recently sold US$1.6m worth of stock

Executive VP & CFO recently sold US$2.1m worth of stock

CEO, President & Director recently sold US$1.0m worth of stock

CEO, President & Director exercised options to buy US$1.2m worth of stock.